Literature DB >> 23357777

Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Andrés Pizzorno1, Yacine Abed, Chantal Rhéaume, Xavier Bouhy, Guy Boivin.   

Abstract

Recombinant influenza A(H1N1)pdm09 wild-type (WT) and zanamivir-resistant E119G and Q136K neuraminidase mutants were generated to determine their enzymatic and replicative properties in vitro, as well as their infectivity and transmissibility in mice and ferrets. Viral titers of recombinant E119G and Q136K mutants were significantly lower than those of the WT in the first 36 h postinoculation (p.i.) in vitro. The E119G and Q136K mutations were both associated with a significant reduction of total neuraminidase (NA) activity at the cell surface of 293T cells, with relative total NA activities of 14% (P < 0.01) and 20% (P < 0.01), respectively, compared to the WT. The E119G mutation significantly reduced the affinity (8-fold increase in Km) but not the Vmax. The Q136K mutation increased the affinity (5-fold decrease in Km) with a reduction in Vmax (8% Vmax ratio versus the WT). In mice, infection with the E119G and Q136K mutants resulted in lung viral titers that were significantly lower than those of the WT on days 3 p.i. (3.4 × 10(6) ± 0.8 × 10(6) and 2.1 × 10(7) ± 0.4 × 10(7) PFU/ml, respectively, versus 8.8 × 10(7) ± 1.1 × 10(7); P < 0.05) and 6 p.i. (3.0 × 10(5) ± 0.5 × 10(5) and 8.6 × 10(5) ± 1.4 × 10(5) PFU/ml, respectively, versus 5.8 × 10(7) ± 0.3 × 10(7); P < 0.01). In experimentally infected ferrets, the E119G mutation rapidly reverted to the WT in donor and contact animals. The Q136K mutation was maintained in ferrets, although nasal wash viral titers from the Q136K contact group were significantly lower than those of the WT on days 3 to 5 p.i. Our results demonstrate that zanamivir-resistant E119G and Q136K mutations compromise viral fitness and transmissibility in A(H1N1)pdm09 viruses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23357777      PMCID: PMC3623354          DOI: 10.1128/AAC.02269-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

2.  Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

Authors:  Thomas Zürcher; Phillip J Yates; Janet Daly; Anjali Sahasrabudhe; Matthew Walters; Laura Dash; Margaret Tisdale; Jennifer L McKimm-Breschkin
Journal:  J Antimicrob Chemother       Date:  2006-08-05       Impact factor: 5.790

3.  Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.

Authors:  Shuji Hatakeyama; Yuko Sakai-Tagawa; Maki Kiso; Hideo Goto; Chiharu Kawakami; Keiko Mitamura; Norio Sugaya; Yasuo Suzuki; Yoshihiro Kawaoka
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  A single sequence change destabilizes the influenza virus neuraminidase tetramer.

Authors:  J M Colacino; N Y Chirgadze; E Garman; K G Murti; R J Loncharich; A J Baxter; K A Staschke; W G Laver
Journal:  Virology       Date:  1997-09-15       Impact factor: 3.616

5.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.

Authors:  M Potier; L Mameli; M Bélisle; L Dallaire; S B Melançon
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

6.  Structural studies of the resistance of influenza virus neuramindase to inhibitors.

Authors:  Brian J Smith; Jennifer L McKimm-Breshkin; Mandy McDonald; Ross T Fernley; Joseph N Varghese; Peter M Colman
Journal:  J Med Chem       Date:  2002-05-23       Impact factor: 7.446

7.  Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.

Authors:  Hui-Ling Yen; Natalia A Ilyushina; Rachelle Salomon; Erich Hoffmann; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

8.  Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Authors:  Aeron C Hurt; Jessica K Holien; Michael Parker; Anne Kelso; Ian G Barr
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

9.  Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.

Authors:  Rebecca J Garten; C Todd Davis; Colin A Russell; Bo Shu; Stephen Lindstrom; Amanda Balish; Wendy M Sessions; Xiyan Xu; Eugene Skepner; Varough Deyde; Margaret Okomo-Adhiambo; Larisa Gubareva; John Barnes; Catherine B Smith; Shannon L Emery; Michael J Hillman; Pierre Rivailler; James Smagala; Miranda de Graaf; David F Burke; Ron A M Fouchier; Claudia Pappas; Celia M Alpuche-Aranda; Hugo López-Gatell; Hiram Olivera; Irma López; Christopher A Myers; Dennis Faix; Patrick J Blair; Cindy Yu; Kimberly M Keene; P David Dotson; David Boxrud; Anthony R Sambol; Syed H Abid; Kirsten St George; Tammy Bannerman; Amanda L Moore; David J Stringer; Patricia Blevins; Gail J Demmler-Harrison; Michele Ginsberg; Paula Kriner; Steve Waterman; Sandra Smole; Hugo F Guevara; Edward A Belongia; Patricia A Clark; Sara T Beatrice; Ruben Donis; Jacqueline Katz; Lyn Finelli; Carolyn B Bridges; Michael Shaw; Daniel B Jernigan; Timothy M Uyeki; Derek J Smith; Alexander I Klimov; Nancy J Cox
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

10.  Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.

Authors:  Michael M Kaminski; Annette Ohnemus; Peter Staeheli; Dennis Rubbenstroth
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

View more
  6 in total

1.  Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.

Authors:  Maki Kiso; Tiago J S Lopes; Seiya Yamayoshi; Mutsumi Ito; Makoto Yamashita; Noriko Nakajima; Hideki Hasegawa; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

2.  Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Authors:  Mélanie Samson; Yacine Abed; François-Marc Desrochers; Stephanie Hamilton; Angela Luttick; Simon P Tucker; Melinda J Pryor; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection.

Authors:  Khristine Kaith S Lloren; Jin Jung Kwon; Won-Suk Choi; Ju Hwan Jeong; Su Jeong Ahn; Young Ki Choi; Yun Hee Baek; Min-Suk Song
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone.

Authors:  Simone E Adams; Vladimir Y Lugovtsev; Anastasia Kan; Nicolai V Bovin; Raymond P Donnelly; Natalia A Ilyushina
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 5.  A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.

Authors:  Yacine Abed; Guy Boivin
Journal:  Open Forum Infect Dis       Date:  2017-05-18       Impact factor: 3.835

6.  Second isirv antiviral group conference: overview.

Authors:  Aeron C Hurt; Michael G Ison; Frederick G Hayden; Alan J Hay
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.